CASE REPORT

Acute Pulmonary Hypertension Crisis after Adalimumab Reduction in Rheumatoid Vasculitis

Gentaro Yamasaki, Mitsumasa Okano, Kazuhiko Nakayama, Naoe Jimbo, Sho Sendo, Naoki Tamada, Kenta Misaki, Yuto Shinkura, Kenichi Yanaka, Hidekazu Tanaka, Kengo Akashi, Akio Morinobu, Hiroshi Yokozaki, Noriaki Emoto and Ken-ichi Hirata

Abstract:

Rheumatoid vasculitis is a rare etiology for pulmonary hypertension (PH) in patients with connective tissue disease. We encountered a case of acute PH crisis in a case with rheumatoid vasculitis eight months after undergoing adalimumab reduction. Since no repetition of arthralgia occurred after the adalimumab reduction, we decided to not increase the dose of adalimumab. However, hemodynamic collapse thereafter developed and even though steroid pulse therapy was administered, the patient nevertheless died. The autopsy showed clusters of acute and chronic inflammation around the remodeled pulmonary arteries along with microthrombi in the vessel lumen. We should consider the possibility of critical worsening of PH as a phenotype of vasculitis related to immunosuppressive therapy reduction.

Key words: rheumatoid arthritis, perivascular inflammation, connective tissue disease, tumor necrosis factor alpha, lymphocyte, cytotoxic T cells

(Intern Med 58: 593-601, 2019) (DOI: 10.2169/internalmedicine.1143-18)

Introduction

Connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) is common in patients with systemic sclerosis (SSc) but rare in those with rheumatoid arthritis (RA) (1, 2). A cohort study in the United Kingdom reported the prevalence of CTD-PAH (n=343) as follows: SSc 76%, mixed connective tissue disease 8%, systemic lupus erythematosus 8%, RA 3%, dermatomyositis and polymyositis 2%, and Sjögren’s syndrome 1% (3). CTD-PAH had a worse prognosis than idiopathic PAH, and SSc-PAH had a worse 1-year survival than any other connective tissue disease (4). However, the prognosis of PAH in RA has been rarely reported. In addition, there are very few cases of PAH in patients with rheumatoid vasculitis (5). The pathology of rheumatoid vasculitis is related to vascular injury by perivascular inflammation and autoimmunity, but the underlying mechanism of PAH development is not fully understood (6). In addition, the efficacy of immunosuppressive therapy in PAH remains unclear.

We herein report a case of acute pulmonary hypertension (PH) crisis in a patient with rheumatoid vasculitis after adalimumab (ADA) reduction.

Case Report

Background with RA

In 2008, a 56-year-old man presented with arthralgia. He was diagnosed with seropositive RA and mild interstitial lung disease (ILD). He had received prednisolone (PSL),...
The clinic all courses of rheumatoid vasculitis. Unstable arthralgia (B) under MZR, SASP, ETN, and PSL (D) was completely controlled by ADA, with no SJC or TJC (B) and a low DAS28 score (C). The high VAS score from 2014 (A) was due to dysesthesia of the toes, cough, and dyspnea, not arthralgia. Consequently, ADA was reduced from August 2015, as his arthritis was stable. ADA: adalimumab, DAS: disease activity score, ETN: etanercept, MZR: mizoribine, SASP: salazosulfapyridine, SJC: swollen joint count, TJC: tender joint count, VAS: visual analogue scale.

As his arthritis was stable, ADA was reduced from 40 mg/2 weeks to 40 mg/3 weeks in August 2015. Six months later, echocardiography detected a tricuspid regurgitation pressure gradient (TRPG) of 60 mmHg, indicating the onset of PH. The clinical course of the patient is shown in Fig. 1 and 2.

The investigation of PAH and diagnosis of rheumatoid vasculitis

In March, 2016 (Day 0), the patient was admitted to our hospital because of his progressive dyspnea (WHO functional class III) and dysesthesia of limbs over the previous eight months after ADA reduction. On admission, his vital signs were as follows: blood pressure 119/85 mmHg, heart rate 76 bpm, respiratory rate 24/min, and saturation 96% with 3 L/min O2 flow. A clinical evaluation revealed jugular venous distension, fine crackles, and leg edema. No skin lesions or arthritis was noted. The laboratory results were as follows: C-reactive protein (CRP) 1.36 mg/dL, ESR 110 mm/h, D-dimer 11.7 μg/mL, serum brain natriuretic peptide 30.1 pg/mL, and Krebs von den Lungen 6 (KL-6) 781 U/mL. He had markedly elevated immunological markers of RA: rheumatoid factor (RF) 1,459 IU/mL, anti-cyclic citrullinated peptide antibody (ACPA) 777 U/mL, and matrix metalloproteinase-3 (MMP3) 226 ng/mL. Antinuclear antibodies were positive at 1:1,280, with homogenous and speckled patterns. No other specific antibodies, including anti-ribonucleoprotein, were positive (Table 1). Immune complexes assessed by a C1q-binding assay and complements were at normal levels.

Chest X-ray (Fig. 3A-C) and chest computed tomography (CT) (Fig. 3D and E) showed persistent ILD findings in the bilateral lower lobes. Ventilation perfusion lung scintigraphy showed no mismatch. Lung function testing revealed restrictive ventilator impairment (%Vital capacity: 59%) and decreased % diffusing capacity of the lung for carbon monox-
According to the time course of the KL-6 levels and the CT findings. The serum level of C₄ was decreased.

Our team, which included cardiologists and rheumatologists, suspected that the main pathology of vasoconstriction was inflammation in the pulmonary arteries due to the activated vasculitis. We judged the PH severity to be moderate and decided to change his drug treatment from oral PSL at 60 mg to intravenous methylprednisolone (M-PSL) at 1,000 mg as steroid pulse therapy on day 17. On day 18, he was intubated for intensive respiratory care. ECG revealed SIQII-IITIII, severe right axis deviation, complete right bundle branch block, and negative T wave of V1-V4, indicating right ventricular load (Fig. 4). Chest X-ray (Fig. 3A-C) and CT (Fig. 3D and E) showed worsening of cardiomegaly and persistent mild ILD findings. Echocardiography showed progression of left ventricular compression forming a D-shape (Fig. 3F-H). Based on the time course of the above findings, further PH progression occurred from day 17-18 and became exacerbated beyond our estimation. We considered introducing pulmonary vasodilators, including epoprostenol, and the induction of intermittent pulse intravenous cyclophosphamide therapy (IVCY), based on the approaches adopted in previous studies (9), but a ventricular fibrillation storm occurred, and he died the same day.

The pathological findings from the autopsy revealed micro-thrombi (Fig. 5A and B) in pulmonary arteries with micro-thrombi (Fig. 5A and B) in pulmonary arteries with micro-thrombi (Fig. 5A and B) in pulmonary arteries with micro-thrombi (Fig. 5A and B) in pulmonary arteries with micro-thrombi (Fig. 5A and B) in pulmonary arteries with micro-thrombi (Fig. 5A and B) in pulmonary arteries with micro-thrombi (Fig. 5A and B) in pulmonary arteries with micro-thrombi (Fig. 5A and B) in pulmonary arteries with micro-thrombi (Fig. 5A and B) in pulmonary arteries with micro-thrombi (Fig. 5A and B) in pulmonary arteries with micro-thrombi (Fig. 5A and B) in pulmonary arteries with micro-thrombi (Fig. 5A and B) in pulmonary arteries with micro-thrombi (Fig. 5A and B) in pulmonary arteries with micro-thrombi (Fig. 5A and B) in pulmonary arteries with micro-thrombi (Fig. 5A and B) in pulmonary arteries with micro-thrombi (Fig. 5A and B) in pulmonary arteries with micro-thrombi (Fig. 5A and B) in pulmonary arteries with micro-thrombi (Fig. 5A and B) in pulmonary arteries with micro-thrombi (Fig. 5A and B) in pulmonary arteries with micro-thrombi (Fig. 5A and B) in pulmonary arteries with micro-thrombi (Fig. 5A and B) in pulmonary arteries with micro-thrombi (Fig. 5A and B) in pulmonary arteries with micro-thrombi (Fig. 5A and B) in pulmonary arteries with
perivascular inflammation, which was compatible with vasculitis. Around the mildly remodeled artery (Fig. 5C and D), indicative of acute inflammation, neutrophils with a few lymphocytes had infiltrated into the vessel wall (Fig. 5E and F). In contrast, around the progressive remodeled artery (Fig. 5G, 6A and B), indicative of chronic inflammation, the majority of the inflammation cells were lymphocytes (Fig. 5H). In addition, both T (Fig. 6C) and B (Fig. 6F) lymphocytes were observed in the perivascular space. CD8+ cytotoxic T cells (Fig. 6E) were more abundant than CD4+ helper T cells (Fig. 6D) on immunohistochemical staining.

**Discussion**

**PAH in RA and rheumatoid vasculitis patients**

PAH in RA is rare, and the prognosis is not well known. A cohort study reported that PAH in RA had a better outcome than idiopathic PAH (10). However, some studies have reported a poor response to therapy targeting inflammatory components, suggesting that early PH screening and the consideration of immunosuppressive therapy in conjunction with vasodilator therapy may be beneficial. Similar to this case, a previous case report described a case of fatal PAH due to rheumatoid vasculitis with mild arthralgia that was refractory to immunosuppressive therapy (5). There may be considerable differences in the severity of PH between RA and rheumatoid vasculitis. We should consider introducing combination therapy with intensive immunosuppressive therapy and pulmonary vasodilators at the early stage of PH, when the pathological changes are still reversible.

**Predictors for PAH development in patients with RA**

Appropriate monitoring for disease activity is an issue in RA patients. Inflammation and immunological markers, including the ESR, CRP, complement, RF, and ACPA levels, have some correlation with the RA disease activity. In the clinical setting, the RA disease activity is often assessed based on the articular involvement using the DAS28 score, with attempts later made to decrease the immunosuppressive therapy. Some patients develop PH, but how to predict these patients remains unclear, as is whether or not these markers work well as predictors of PH development. In the present case, the elevated levels of CRP, RF, and ACPA and the low levels of complement were correlated with the severity of PH. We should not dismiss complaints of dyspnea in patients with mild arthritis, which may indicate complications of PH or lung diseases. The early physiological evaluation of respiratory symptoms and screening tests for PH, such as echocardiography, are recommended (11). In the present RA patient, we should have suspected PH as a complication of vasculitis earlier. We need to monitor the status of PH with frequent ECG, chest X-ray, and echocardiography. On detecting PH, we should consider performing further examinations, including RHC, through good teamwork between cardiologists and rheumatologists.

**PH crisis**

We herein report an instructive case drawing attention to PH crisis related to immunosuppressive therapy reduction in a patient with rheumatoid vasculitis. Despite the presence of mild ILD, we diagnosed the patient with PH due to vasculitis as the main pathology because of the time course of his symptoms, inflammation markers (CRP and ESR), KL-6 levels, CT findings, and pathological findings. The neurological symptoms and elevated ESR without worsening of arthritis indicated the presence of underlying vasculitis (12) in 2014. In addition, the ADA reduction in 2015 was unlikely to have triggered the PH crisis, as it was resistant to steroid therapy. We were able to eliminate acute massive pulmonary embolism as well, since it was deemed unlikely during the crisis based on the autopsy findings.

In this rheumatoid vasculitis patient, we should have been aware of the risk of rapid progression towards PH crisis. On day 17, the simultaneous introduction of pulmonary vasodilators, including epoprostenol, and inotropic agents was suspended due to the moderate severity of PH based on the result of the second RHC. In addition, another increase in the dose of ADA was also suspended due to previous concerns.

**Table 1. Serological Markers of Autoimmune Disease.**

| Serological markers | Values (Normal range) |
|---------------------|-----------------------|
| Rheumatoid factor (IU/mL) | 1,459 (~15) |
| ACPA (U/mL) | 777 (~4.5) |
| MMP3 (ng/mL) | 249 (17-121) |
| Anti-nuclear antibody | 1:1,280 (~1:40) |
| dsDNA (U/mL) | 2.6 (~12) |
| ssDNA (AU/m) | 7.8 (~25) |
| Sm (Um) | 2.5 (~10) |
| U1-RNP (U/mL) | 0.8 (~10) |
| SS-A/ Ro (U/mL) | 0.6 (~10) |
| SS-B/La (U/mL) | 0.3 (~10) |
| Scl-70 (U/mL) | <5 (~10) |
| Centromere (U/mL) | <5 (~10) |
| RNA polymerase III (index) | <5 (~28) |
| Jo-1 (U/mL) | <5 (~9) |
| ARS (index) | <5 (~25) |
| Cardiolipin (U/mL) | 3.0 (~10) |
| CLβ2GPI complex (U/mL) | <0.7 (~3.5) |
| Lupus anticoagulant | 0.8 (~1.3) |
| c-ANCA (U/mL) | 0.1 (~5) |
| p-ANCA (U/mL) | 0.1 (~5) |

ACPA: anti-cyclic citrullinated peptide antibodies, ANCA: antineutrophil cytoplasmic antibodies, ARS: aminoacyl-tRNA synthetases antibodies, CLβ2GPI: cardiopin $\beta$ 2–glycoprotein I, dsDNA: double-strand DNA, MMP3: matrix metalloproteinase-3, Scl-70: topoisomerase I, Sm: smith, SS-A: Sjögren’s-syndrome-related antigen A, SS-B: Sjögren’s-syndrome-related antigen B, ssDNA: single-strand DNA, U1-RNP, U1-ribonucleoprotein.
Figure 3. Clinical images during PH worsening. Chest X-ray (A-C) shows worsening of cardiomegaly. Chest computed tomography shows dilated pulmonary arteries (D) and mild interstitial lung disease (E). Trans-thoracic echocardiography (F-H) detects a D-shaped left ventricle. Brain MRI (FLAIR) shows multiple old cerebral infarctions (I, J).

about its adverse effects on chronic heart failure under TNFα pathway inhibition (13). Furthermore, we should have introduced inhaled nitric oxide as an additional pulmonary vasodilator and also considered performing percutaneous
cardiopulmonary support to manage the hemodynamics until the intensive drug administration sufficiently improved the pathology. However, our underestimation of the severity and progression of PAH ultimately led to the delayed introduction of intensive therapy, which thus failed to prevent hemodynamic collapse and the subsequent fatal events.

A previous case report of a patient with PH-associated systemic sclerosis described similar clinical worsening and death after the cessation of infliximab (14). In a rat model of monocrotaline-induced PAH, etanercept prevented PAH by reducing inflammatory cell infiltration (15). These reports suggest the critical involvement of the TNFα pathway.

**Table 2. Time Course of Hemodynamics and Oxygenation.**

| Variables              | Day 8  | Day 17 |
|------------------------|--------|--------|
| RAP (mmHg)             | 15     | 6      |
| mPAP (mmHg)            | 43     | 52     |
| PCWP (mmHg)            | 9      | 6      |
| Cardiac index (L/min/m²)| 3.1    | 3.3    |
| PVR (dyne*sec/cm²)     | 456    | 586    |
| SVR (dyne*sec/cm²)     | 1,087  | 1,045  |
| SBP (mmHg)             | 119    | 109    |
| DBP (mmHg)             | 85     | 76     |
| Heart rate (/min)      | 76     | 97     |
| SaO2 (%)               | 86.7   | 82.6   |
| PaO₂ (%)               | 52.6   | 48.6   |
| A-aDO₂ (mmHg)          | 60.3   | 272.7  |
| PaO₂/FiO₂ (mmHg)       | 250.5  | 97.2   |
| O₂ condition           | room   | FiO₂ 50% NPPV |

Dose of prednisolone after the RHC: 60mg * 7 days, 1g * 1 day

A-aDO₂: partial pressure difference of alveolar-arterial oxygen, DBP: diastolic blood pressure, FiO₂: fraction of inspired oxygen, NPPV: non-invasive positive pressure ventilation, mPAP: mean pulmonary arterial pressure, PaO₂: partial pressure of arterial oxygen, PCWP: pulmonary capillary wedge pressure, PVR: pulmonary vascular resistance, RAP: right atrial pressure, SaO₂: arterial saturation of oxygen, SBP: systolic blood pressure, SVR: systemic vascular resistance

**Figure 4.** Time course of ECG after PH development. Electrocardiography shows SIQIIITIII and severe right axis deviation on day 18. According to the time course, ICRBBB changed to CRBBB. The negative T wave of V1-V4 indicates right ventricular load. ICRBBB: incomplete right bundle branch block, CRBBB: complete right bundle branch block.
Pathological features of the pulmonary arteries in rheumatoid vasculitis

In this case, we documented histologically proven pulmonary vasculitis, which may help improve our understanding of the mechanism underlying PAH development. A pathological examination revealed the multiple pathognomical features located in the pulmonary arteries including micro-thrombi, acute inflammation, chronic inflammation, and fibroelastic intimal proliferation. Nonspecific interstitial pneumonia was observed in the bilateral lower lobes without significant active inflammation. Neutrophils and macrophages with a few lymphocytes were found to have infiltrated into the progression of PH.
the vessel wall around the mildly remodeled artery showing mild intimal thickening along with destruction of the elastic lamina, indicating an acute inflammation area. In contrast, around the progressively remodeled artery showing extensive fibroelastic proliferation of the intima and media to the point of luminal occlusion, the perivascular inflammation cells mainly consisted of lymphocytes, indicating a chronic inflammation area.

In systemic rheumatic diseases, imbalances in the numbers and fractions of T cell subsets are key pathogenic derangements (16). CD8+ cytotoxic T cells were more abundant than other T cells in the present case, indicating that CD8+ T cells had a role in the PAH progression. We are interested in the potential efficacy against PAH of abatacept, a cytotoxic T lymphocyte-associated antigen 4 immunoglobulin fusion protein that may reduce the number of cytotoxic T cells (17). Further studies exploring the efficacy of biologic disease modifying anti-rheumatic drugs against PAH, including TNF inhibitors and interleukin (IL)-6 receptor antagonists, are being conducted in the TRANSFORM-UK study, and clinical trials (18) are warranted.

Conclusion

We encountered a case of PH crisis associated with histologically proven rheumatoid vasculitis after ADA reduction. Physicians should be alert for the potential development of PAH in RA patients due to vasculitis. An appropriate monitoring system for PH development is needed. Although there are few cases of PAH associated with rheumatoid vasculitis, we should bear in mind the possibility of critical worsening of PH due to the reduction of immunosuppressive therapy in RA patients.

Author’s disclosure of potential Conflicts of Interest (COI).
Kazuhiko Nakayama: Research funding, Acterion Pharmaceutical Japan, Bayer Holding and GlaxoSmithKline. Noriaki Emoto: Research funding, Nippon Shinyaku. Ken-ichi Hirata: Research funding, Actelion Pharmaceuticals Japan and Bayer Holding.

Gentaro Yamasaki and Mitsumasa Okano contributed equally to this work.

References

1. Castro GWR, Appenzeller S, Bertolo MB, Costallat LTL. Isolated pulmonary hypertension secondary to rheumatoid arthritis. Clin Rheumatol 25: 901-903, 2006.

2. Panagiotidou E, Sourla E, Kotoulas SX, et al. Rheumatoid arthritis associated pulmonary hypertension: clinical challenges reflecting the diversity of pathophysiology. Respir Med Case Reports 20: 164-167, 2017.

3. Condliffe R, Kiely DG, Peacock AJ, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 179: 151-157, 2009.

4. Chung L, Liu J, Parsons L, et al. Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 138: 1383-1394, 2010.

5. Balagopal VP, Da Costa P, Greenstone MA. Fatal pulmonary hypertension and rheumatoid vasculitis. Eur Respir J 8: 331-333, 1995.

6. Kishore S, Maher L, Majithia V. Rheumatoid vasculitis: a diminishing yet devastating menace. Curr Rheumatol Rep 19: 39, 2017.

7. Scott DGI, Bacon PA. Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis. Am J Med 76: 377-384, 1984.

8. Ntatsaki E, Mooney J, Scott DGI, Watts RA. Systemic rheumatoid vasculitis in the era of modern immunosuppressive therapy. Rheumatol (United Kingdom) 53: 145-152, 2014.

9. Miyamichi-Yamoto S, Fukumoto Y, Sugimura K, et al. Intensive immunosuppressive therapy improves pulmonary hemodynamics and long-term prognosis in patients with pulmonary arterial hypertension associated with connective tissue disease. Circ J 75: 2668-2674, 2011.

10. Sadeghi S, Granton JT, Akhavan P, et al. Survival in rheumatoid arthritis-associated pulmonary arterial hypertension compared with idiopathic pulmonary arterial hypertension. Respirology 20: 481-487, 2015.

11. Reeves GEM, Collins N, Hayes P, et al. SAPHIRE: Stress and pulmonary hypertension in rheumatoid evaluation - a prevalence study. Int J Rheumatol 2016: 4564531, 2016.

12. Collins MP. The vasculitic neuropathies: an update. Curr Opin Neurol 25: 573-585, 2012.

13. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure. Circulation 107: 3133-3140, 2003.

14. Bargagli E, Galeazzi M, Bellissi F, Volterrani L, Rottoli P. Infliximab treatment in a patient with systemic sclerosis associated with lung fibrosis and pulmonary hypertension. Respiration 75: 346-349, 2008.

15. Zhang LL, Lu J, Li MT, Wang Q, Zeng XF. Preventive and remedia l application of etanercept attenuate monocrotaline-induced pulmonary arterial hypertension. Int J Rheum Dis 19: 192-198, 2016.

16. Gizinski AM, Fox DA. T cell subsets and their role in the pathogenesis of rheumatic disease. Curr Opin Rheumatol 26: 204-210, 2014.

17. Bonelli M, Gischi L, Blümli S, et al. Abatacept (CTLA-4Ig) treatment reduces T cell apoptosis and regulatory T cell suppression in patients with rheumatoid arthritis. Rheumatol (United Kingdom) 55: 710-720, 2016.

18. Hernandez-Sanchez J, Harlow L, Church C, et al. Clinical trial protocol for TRANSFORM-UK: a therapeutic open-label study of tocilizumab in the treatment of pulmonary arterial hypertension. Pulm Circ 8: 2045895217735820, 2018.

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).